DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,413,000 | +5.8% | 6,363 | +2.5% | 0.10% | -4.0% |
| Q3 2020 | $1,336,000 | +35.1% | 6,206 | +10.9% | 0.10% | +7.5% |
| Q2 2020 | $989,000 | +26.8% | 5,595 | -0.7% | 0.09% | +3.3% |
| Q1 2020 | $780,000 | -8.5% | 5,634 | +1.6% | 0.09% | +20.0% |
| Q4 2019 | $852,000 | +8.1% | 5,548 | +1.7% | 0.08% | +8.7% |
| Q3 2019 | $788,000 | +8.4% | 5,454 | +7.3% | 0.07% | +13.1% |
| Q2 2019 | $727,000 | +16.9% | 5,084 | +7.9% | 0.06% | +15.1% |
| Q1 2019 | $622,000 | +30.4% | 4,710 | +1.8% | 0.05% | +15.2% |
| Q4 2018 | $477,000 | -0.6% | 4,627 | +4.6% | 0.05% | +17.9% |
| Q3 2018 | $480,000 | +11.6% | 4,422 | +1.5% | 0.04% | +2.6% |
| Q2 2018 | $430,000 | +0.5% | 4,357 | -0.2% | 0.04% | -2.6% |
| Q1 2018 | $428,000 | +105.8% | 4,367 | +64.8% | 0.04% | +34.5% |
| Q3 2016 | $208,000 | -41.9% | 2,650 | -44.5% | 0.03% | -67.8% |
| Q1 2014 | $358,000 | +1.1% | 4,775 | +4.1% | 0.09% | -4.3% |
| Q4 2013 | $354,000 | +18.8% | 4,585 | +7.1% | 0.09% | +14.6% |
| Q3 2013 | $298,000 | +30.7% | 4,280 | +17.6% | 0.08% | +24.2% |
| Q2 2013 | $228,000 | – | 3,640 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |